0001193125-26-174454.txt : 20260423 0001193125-26-174454.hdr.sgml : 20260423 20260423211924 ACCESSION NUMBER: 0001193125-26-174454 CONFORMED SUBMISSION TYPE: SCHEDULE 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20260423 DATE AS OF CHANGE: 20260423 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Damora Therapeutics, Inc. CENTRAL INDEX KEY: 0001800315 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 371957007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-91812 FILM NUMBER: 26890212 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: (781) 281-9020 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Galecto, Inc. DATE OF NAME CHANGE: 20201029 FORMER COMPANY: FORMER CONFORMED NAME: Galecto Inc. DATE OF NAME CHANGE: 20200116 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Paragon Therapeutics, Inc. CENTRAL INDEX KEY: 0001861055 ORGANIZATION NAME: EIN: 862707757 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A BUSINESS ADDRESS: STREET 1: C/O FAIRMOUNT FUNDS MANAGEMENT, LLC STREET 2: 2001 MARKET STREET, SUITE 2500 CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: (267) 760-4066 MAIL ADDRESS: STREET 1: C/O FAIRMOUNT FUNDS MANAGEMENT, LLC STREET 2: 2001 MARKET STREET, SUITE 2500 CITY: PHILADELPHIA STATE: PA ZIP: 19103 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001861055 XXXXXXXX LIVE 1 Common Stock, par value $0.00001 per share 02/09/2026 0001800315 Damora Therapeutics, Inc. 36322Q206 221 Crescent Street Building 23, Suite 105 Waltham MA 02453 Rule 13d-1(c) Paragon Therapeutics, Inc. DE 2045473 0.00 2045473 0.00 2045473 N 3.39 CO Row 11 is based on 60,303,212 shares of Common Stock outstanding as of March 17, 2026 as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission on March 19, 2026. Damora Therapeutics, Inc. 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453 Paragon Therapeutics, Inc. 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453 Delaware Y See the response to Item 9 on the attached cover page. See the response to Item 11 on the attached cover page. See the response to Item 5 on the attached cover page. See the response to Item 6 on the attached cover page. See the response to Item 7 on the attached cover page. See the response to Item 8 on the attached cover page. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Paragon Therapeutics, Inc. /s/ Keri Lantz 04/23/2026